Treatment of Bleeding in Severe Hemorrhagic Pancreatitis with Recombinant Factor VIIa

Schuster, Rob; Lee, Sarah J.; Rink, Donald
November 2003
American Surgeon;Nov2003, Vol. 69 Issue 11, p1017
Academic Journal
Recombinant factor VIIa (rFVIIa) has been used to treat bleeding complications in patients with hemophilia. It acts at the site of vessel injury, forming a complex with tissue factor to activate the clotting cascade. Recent reports have shown rFVIIa may be a useful hemostatic agent in patients after obstetrical, urologic, trauma, or transplant procedures. We report the first documented case of bleeding from hemorrhage pancreatitis treated with rFVIIa.


Related Articles

  • Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX. Lyseng-Williamson, Katherine A.; Plosker, Greg L. // PharmacoEconomics;2007, Vol. 25 Issue 12, p1007 

    Recombinant factor VIIa (NovoSeven®; also known as recombinant activated factor VII or eptacog alfa) is indicated as an intravenous haemostatic agent in haemophilia patients with inhibitors to clotting factors VIII or IX. In noncomparative trials in haemophilia patients with inhibitors,...

  • Determinants of drug costs in hopitalised patients with haemophilia: impact of recombinant activated factor VII. Galanaud, Jean Philippe; Pelletier-Fleury, Nathalie; Logerot-Lebrun, Hélène; Lambert, Thierry // PharmacoEconomics;2003, Vol. 21 Issue 10, p699 

    Objective: To analyse the determinants of anti-haemophilic drug costs in hospitalised patients with haemophilia and to estimate the impact of recombinant activated factor VII (rFVIIa) therapy on this expenditure.Perspective: The perspective of the study was from the...

  • Recombinant Factor VIIa: Hemostatic Adjunct in the Coagulopathic Burn Patient. Martin, Jeremiah T.; Alkhoury, Fuad; McIntosh, Bryan C.; Fidler, Phillip; Schulz, John // ePlasty: Open Access Journal of Plastic Surgery;2009, Vol. 9, p262 

    Introduction: Recombinant factor VIIa (rFVIIa; NovoSeven) is well recognized as an effective hemostatic agent in the management and prophylaxis of patients with hemophilia.We report here the successful use of rFVIIa in a coagulopathic burn patient. Methods: A 63-year-old man was admitted with...

  • Treatment of an Acquired Coagulopathy with Recombinant Activated Factor VII in a Damage-Control Patient. Holcomb, John B.; Hoots, Keith; Moore, Fredrick A. // Military Medicine;Apr2005, Vol. 170 Issue 4, p287 

    Recombinant activated factor VII is commonly used for the treatment of hemophiliac patients with inhibitors and has been studied for use in trauma. We report the use of recombinant activated factor VII for a male patient who was injured in a motor vehicle accident. We also summarize the animal...

  • A Massive Transfusion Protocol Incorporating a Higher FFP/RBC Ratio Is Associated With Decreased Use of Recombinant Activated Factor VII in Trauma Patients. Tan, Josenia N. M.; Burke, Peter A.; Agarwal, Suresh K.; Mantilla-Rey, Nelson; Quillen, Karen // American Journal of Clinical Pathology;Apr2012, Vol. 137 Issue 4, p566 

    We implemented a protocol incorporating a higher fresh frozen plasma (FFP)/RBC ratio for the management of trauma patients requiring massive transfusion in 2007. This study aims to identify issues that affected the effective deployment of the massive transfusion protocol (MTP) and compare...

  • Renal Hemophilic Pseudotumors. Gürkan, Emel // Journal of Coagulation Disorders;2010, Vol. 2 Issue 2, p1 

    Severe hemophilic patients are prone to develop long-term sequelae such as pseudotumor formation caused by repeated and unresolved hematomas leading to subsequent encapsulated mass lesion. Among these, renal hemophilic pseudotumors are seen as a rather rare event. Once developed, this serious...

  • Acquired hemophilia A presenting in an elderly man. Woods, Stacy; Varghese, Boji // CMAJ: Canadian Medical Association Journal;8/14/2007, Vol. 177 Issue 4, p341 

    The article discusses several important diagnostic techniques for treating acquired hemophilia A. It is stated that the diagnosis of acquired hemophilia is based on prolonged activated partial thromboplastin time which should be corrected by mixing equal volumes of patient's plasma and the...

  • Prophylaxis in Patients with Severe Hemophilia and Inhibitor. Jimenez-Yuste, Victor; Alvarez, Maria Teresa; Martin-Salces, Monica; Rodriguez-Merchan, E. Carlos; Butta, Nora; Fernandez-Bello, Ihosvany; Rivas, Isabel; Rodriguez de la Rua, Ana // Journal of Coagulation Disorders;2009, Vol. 1 Issue 1, p1 

    Joint hemorrhage, the most common manifestation of severe hemophilia, frequently leads to recurrent hemarthrosis, chronic synovitis, and arthropathy. The main goal of replacement therapy is to prevent this pathology. On-demand treatment slows, but does not prevent, the progression of...

  • In cold blood. Day, Michael // New Scientist;01/03/98, Vol. 157 Issue 2115, p5 

    Looks at whether the British government is doing enough for haemophiliacs, with reference to criticism of a government program aimed at determining whether haemophiliacs are at risk of contracting Creutzfeldt-Jakob disease from clotting factors. Comments from Christopher Ludlam of the Western...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics